Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 53.33

-0.4%

Nov 26 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (3536)	4/22/2001 11:24:48 PM
From: aknahow	Read Replies (2) of 52153

If people are willing to stop treatment and hope the clearance phase last a long time Amevive may have a cost advantage. To some extent this will be offset by having to monitor T-Cells with blood test and having to get the I.V. from a doctor when it is needed. I am no longer as sure as I was that people will just be happy to not have to go to the doctor, for months at a time as clearance persist. Have a better understanding of why some will prefer to take a self administered weekly or biweekly subcutaneous injection forever to avoid an unexpected outbreak. I remember your previous post about trafficking of t-Cells, so I do understand there may be safety concerns for both products. But since Xanelim does not deplete T-Cells and Amevive does, Xanelim may be safer. I am not dismissing Enbrel, I am just don't understand the area well enough to discuss it. I really, also do not have any valid opinion on how Amevive and Xanelim compare head to head. Have been told one can't compare head to head because the trials were quite distinct or the data released does not permit it. Have even less of an idea if either or both will make it thru the FDA.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next